放射性碘难治性甲状腺乳头状癌的治疗：良好的临床和生化反应。

IF 9.6 3区医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Clinical Nuclear Medicine Pub Date : 2025-05-01 Epub Date: 2025-04-07 DOI:10.1097/RLU.0000000000005728

Nasrin Raeisi, Amin Saber Tanha, Mohammad Hossein Gozashti, Zahra Kiamanesh, Kamran Aryana

{"title":"放射性碘难治性甲状腺乳头状癌的治疗：良好的临床和生化反应。","authors":"Nasrin Raeisi, Amin Saber Tanha, Mohammad Hossein Gozashti, Zahra Kiamanesh, Kamran Aryana","doi":"10.1097/RLU.0000000000005728","DOIUrl":null,"url":null,"abstract":"We report a 38-year-old man with radio-iodine refractory papillary thyroid carcinoma (RAIR PTC) who experienced significant relief from symptoms and showed a positive biochemical response after undergoing a single cycle of 177Lu-FAPI-2286 therapy. A pretreatment 99mTc-FAPI-46 scan showed diffuse uptake throughout both lungs and subsequent serial post-treatment scans demonstrated sustained uptake in pulmonary metastases. After treatment, there was a significant decline in serum thyroglobulin levels, accompanied by a remarkable improvement in symptoms, leading to near-complete resolution. This case highlights the potential of 177Lu-FAPI-2286 therapy as an effective treatment option for RAIR PTC patients.","PeriodicalId":10692,"journal":{"name":"Clinical Nuclear Medicine","volume":"50 5","pages":"e315-e316"},"PeriodicalIF":9.6000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"177Lu-FAPI-2286 Therapy in a Patient With Radio-iodine Refractory Papillary Thyroid Carcinoma: A Favorable Clinical and Biochemical Response.\",\"authors\":\"Nasrin Raeisi, Amin Saber Tanha, Mohammad Hossein Gozashti, Zahra Kiamanesh, Kamran Aryana\",\"doi\":\"10.1097/RLU.0000000000005728\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"We report a 38-year-old man with radio-iodine refractory papillary thyroid carcinoma (RAIR PTC) who experienced significant relief from symptoms and showed a positive biochemical response after undergoing a single cycle of 177Lu-FAPI-2286 therapy. A pretreatment 99mTc-FAPI-46 scan showed diffuse uptake throughout both lungs and subsequent serial post-treatment scans demonstrated sustained uptake in pulmonary metastases. After treatment, there was a significant decline in serum thyroglobulin levels, accompanied by a remarkable improvement in symptoms, leading to near-complete resolution. This case highlights the potential of 177Lu-FAPI-2286 therapy as an effective treatment option for RAIR PTC patients.\",\"PeriodicalId\":10692,\"journal\":{\"name\":\"Clinical Nuclear Medicine\",\"volume\":\"50 5\",\"pages\":\"e315-e316\"},\"PeriodicalIF\":9.6000,\"publicationDate\":\"2025-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Nuclear Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/RLU.0000000000005728\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/4/7 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Nuclear Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/RLU.0000000000005728","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/7 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

摘要

我们报告一位38岁的放射性碘难治性甲状腺乳头状癌（RAIR PTC）患者，在接受单周期的177Lu-FAPI-2286治疗后，症状明显缓解，生化反应阳性。预处理99mTc-FAPI-46扫描显示双肺弥漫性摄取，随后的一系列治疗后扫描显示肺转移灶持续摄取。治疗后，血清甲状腺球蛋白水平显著下降，症状显著改善，几乎完全缓解。该病例强调了177Lu-FAPI-2286治疗作为RAIR PTC患者有效治疗选择的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

177Lu-FAPI-2286 Therapy in a Patient With Radio-iodine Refractory Papillary Thyroid Carcinoma: A Favorable Clinical and Biochemical Response.

We report a 38-year-old man with radio-iodine refractory papillary thyroid carcinoma (RAIR PTC) who experienced significant relief from symptoms and showed a positive biochemical response after undergoing a single cycle of 177Lu-FAPI-2286 therapy. A pretreatment 99mTc-FAPI-46 scan showed diffuse uptake throughout both lungs and subsequent serial post-treatment scans demonstrated sustained uptake in pulmonary metastases. After treatment, there was a significant decline in serum thyroglobulin levels, accompanied by a remarkable improvement in symptoms, leading to near-complete resolution. This case highlights the potential of 177Lu-FAPI-2286 therapy as an effective treatment option for RAIR PTC patients.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical Nuclear Medicine 医学-核医学

CiteScore

2.90

自引率

31.10%

发文量

1113

审稿时长

2 months

期刊介绍： Clinical Nuclear Medicine is a comprehensive and current resource for professionals in the field of nuclear medicine. It caters to both generalists and specialists, offering valuable insights on how to effectively apply nuclear medicine techniques in various clinical scenarios. With a focus on timely dissemination of information, this journal covers the latest developments that impact all aspects of the specialty. Geared towards practitioners, Clinical Nuclear Medicine is the ultimate practice-oriented publication in the field of nuclear imaging. Its informative articles are complemented by numerous illustrations that demonstrate how physicians can seamlessly integrate the knowledge gained into their everyday practice.